EspaƱol
ABOUT US | CONTACT | VOLUNTEER
MISSION & MINISTRY
Find a Physician
Decrease (-) Restore Default Increase (+)

Afinitor Approval Expanded to Include Benign Kidney Tumors

Growths caused by rare genetic disease

FRIDAY, April 27 (HealthDay News) -- Afinitor (everolimus) is the first drug to be approved by the U.S. Food and Drug Administration to treat benign kidney tumors among people with a rare genetic condition called tuberous sclerosis complex (TSC), the agency said in a news release.

TSC causes non-cancerous tumors of the brain, kidney and other organs, the FDA said. The disease affects up to 40,000 people in the United States, and as many as 80 percent develop kidney problems.

Afinitor helps suppress these tumors by blocking a protein that's essential for their development and growth, the FDA said.

The drug's safety and effectiveness were clinically evaluated among 118 people with TSC. The most common side effects were inflamed or sore mouth, nausea and vomiting, acne, eczema, cough, headache, diarrhea, abdominal pain, joint pain and swelling of the legs or arms. Some 15 percent of females who took Afinitor missed at least one menstrual period.

Afinitor was first approved by the FDA in 2009 to treat kidney tumors that weren't treated successfully with other drugs.

Afinitor is produced by Novartis, based in East Hanover, N.J.

More information

To learn more about this drug, visit the U.S. National Cancer Institute.


Copyright © 2012 HealthDay. All rights reserved.

About Us



Emanuel Cancer Centers 2013 Annual Report
Joint Notice of Privacy Practices
Accreditation & Quality Measures
Board of Directors
CEO's Message
Community Crisis Information
Maps & Directions
Mission & Ministry
News & Publications
Volunteer

Care & Services



Emanuel Physician Finder

Employees & Physicians



Tenet Application Process
e-MC Physician Portal
Web Mail
Employment Services
Physician Verification
Living in Turlock
Contact Us

Emanuel Medical Center
825 Delbon Avenue
Turlock, CA 95382
(209) 667-4200
Contact Us
© 2014 Emanuel Medical Center, Inc. All rights reserved
Home   |   Site Map   |   Joint Notice of Privacy Practices